

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Weydt, Patrick

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Neurologist

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Freie Universität Berlin	MD	05/2000	Medicine (<i>summa cum laude</i>)
University of Washington, Seattle	Postdoctoral	09/2006	Neuroscience
Ulm University	Boards	05/2013	Neurology
Ulm University	Habilitation	02/2016	General Neurology
Bonn University	Faculty	02/2021	General Neurology

A. Personal Statement

I am a board certified neurologist at the University Hospital in Bonn, Germany, and have an affiliation as a clinician-scientist at the German Center for Neurodegenerative Diseases (DZNE) in Bonn.

At the University Hospital Bonn I run the Motoneuron disease clinic (ALS and SMA), which has expanded under my tenure from 30 to currently more than 250 patients per year. In addition, I head the Huntington's disease clinic, which I founded in 2016 and which sees around 100 patients per year. At the DZNE we run phase II and phase III trials (including ASO trials). My clinical and research efforts are driven by the conviction that providing excellent patient care today will attract patient populations to participate in translational innovative research programs that will enable the development of transformational treatment strategies tomorrow. My work has contributed to the establishment of informative and innovative biomarkers, such as neurofilaments, troponins and body weight. The regulatory implications have lead to me being selected as a permanent member of the Science Advisory Group (SAG) Neurology of the European Medicines Agency (EMA) in 2020.

I have a background in investigating metabolic and inflammatory aspects of neurodegeneration in general and ALS and Huntington disease in particular at the laboratory and clinical level. As PI or co-Investigator on several university- and industry-funded grants, work at the interface of clinical and basic research of two paradigmatic diseases. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget. Patient and community out-reach is very important to me and I organize the very successful "Bonner ALS Tag" series since 2018 and run social media channels on YouTube, X and Instagram (@als_doc, @huntington_doc)

Bibliographical indices (Google Scholar 1.6.2024): h-index: 45; Citations: 8370

Recent relevant publications:

1. Meyer T, Schumann P, **Weydt P**, Petri S, Koc Y, Spittel S, Bernsen S, Günther R, Weishaupt JH, Dreger M, Kolzarek F, Kettemann D, Norden J, Boentert M, Vidovic M, Meisel C, Münch C, Maier A, Körtvélyessy P. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice. *Muscle Nerve*. 2023 Jun;67(6):515-521. doi: 10.1002/mus.27818. Epub 2023 Apr 3. PMID: 36928619
2. Kittipeerapat N, Fabian R, Bernsen S, **Weydt P***, Castro-Gomez S. Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis. *Int J Mol Sci*. 2023 Jul 20;24(14):1168
3. Dorst J, **Weydt P****, Brenner D, Witzel S, Kandler K, Huss A, Herrmann C, Wiesenfarth M, Knehr A, Günther K, Müller K, Weishaupt JH, Prudlo J, Forsberg K, Andersen PM, Rosenbohm A, Schuster J, Roselli F, Dupuis L, Mayer B, Tumani H, Kassubek J, Ludolph AC. Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriers. *EBioMedicine*. 2023 Apr;90:104521.
4. Lipsmeier F, Simillion C, Bamdadian A, Tortelli R, Byrne LM, Zhang YP, Wolf D, Smith AV, Czech C, Gossens C, **Weydt P**, Schobel SA, Rodrigues FB, Wild EJ, Lindemann M. A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study. *J Med Internet Res*. 2022 Jun 28;24(6):e32997.
5. Castro-Gomez S, Radermacher B, Tacik P, Mirandola SR, Heneka MT, **Weydt P**. Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosis. *Brain Commun*. 2021 Nov 17;3(4)
6. Meyer T, Schumann P, Weydt P, Petri S, Koc Y, Spittel S, Bernsen S, Günther R, Weishaupt JH, Dreger M, Kolzarek F, Kettemann D, Norden J, Boentert M, Vidovic M, Meisel C, Münch C, Maier A, Körtvélyessy P. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice. *Muscle Nerve*. 2023 Jun;67(6):515-521. doi: 10.1002/mus.27818. Epub 2023 Apr 3. PMID: 36928619

* shared last authorship, ** shared first authorship

B. Positions, Scientific Appointments, and Honors

Positions and Scientific Appointments

10/2016-present	Consultant Neurologist, Research Group Leader, Department of Neurodegenerative Diseases, Bonn University/DZNE
2016	Habilitation, Clinical Neurology, Ulm University (Umhabilitation to Bonn 2021)
2013-2016	Board certified Neurologist, Department of Neurology, Ulm University
2006-2013	Residency Department of Neurology, Ulm University
2009-2010	Residency Department of Psychiatry, Ulm University
2003-2006	Senior Fellow, Dept. Lab Medicine, University of Washington
2000-2003	Senior Fellow, Dept. Neurology, University of Washington
1997-2000	Residency Department of Neurology, LMU Munich

Honors (selection)

- 2023 Poster Prize ENCALS meeting Barcelona
- 2022 3rd Prize, Pflegepreis der DGN (Patient Care Award, German Society of Neurology)
- 2021-ongoing Member of the Scientific Advisory Group (SAG) of the European Medicines Agency (EMA) (2021-)
- 2018-ongoing Co-Chair of the Executive Committee (EC) of the European Huntington Disease Network (EHDN); Chair of the Program Committee of the EHDN Plenary Meeting 2020-2023, including two virtual meetings
- 2017 Poster Prize ENCALS meeting Tours, France
- 2020-ongoing Founder and Speaker of the B-Centers for Motoneuron Diseases and for Choreatic Movement Disorders at the Center for Rare Diseases Bonn (ZSEB)
- 2016 Elected Member of the Executive Committee (EC) of the European Huntington Disease Network (EHDN)
- 2012-16 Elected member of the Scientific and Bioethical Advisory Board (SBAC) of the European Huntington Disease Network (EHDN)
- 2012 Seed Grant EHDN: Smartphone App and Kinect as tools to assess motor function in Huntington Disease – a Pilot Study (12,500 €)
- 2011 Head of the Organizing Committee of the FENS/IBRO Summer School on „Metabolic Aspects of Chronic Brain Disease“ Reisenburg (ca. 32,000 €)
- 2009 Pilot Grant Thierry Latran Foundation „The role of PGC-1 in ALS“ (100,000 €)
- 2009 Poster Prize Neurogenetics, Deutsche Gesellschaft für Neurologie
- 2009 Head of the Organizing Committee of the PENS Summer School on „Metabolic Aspects of Chronic Brain Disease“ Reisenburg (40,000 €)
- 2005 Platform Presentation “PGC-1 transcription interference produces deranged thermoregulation in Huntington’s disease transgenic mice”, ASHG meeting, Salt Lake City, UT, USA
- 2005 Travel Stipend (\$US 1.500), Route28 Summit “Restoring Mobility: Stem Cells and the Spinal Cord“, Blaine, WA, USA
- 2005 “Career Development Award”, Muscular Dystrophy Association (MDA) (\$US150.000) “VEGF Gene-therapy Strategies for Motor Neuron Disease” (MDA3981) (award abandoned 2006 to return to Germany)
- 2005 “Young Investigator Travel Award” (US\$1.200) and oral presentation, Gordon Research Conference on CAG Repeat Disease, Mount Holyoke
- 2000 Fellowship of the „Deutschen Akademie der Naturforscher Leopoldina“ (Halle, Saale) (ca. €50,000), “Die Rolle der Mikroglia in ALS”

Complete List of Published Work in MyBibliography:

<https://pubmed.ncbi.nlm.nih.gov/?term=weydt+p&sort=date>

Clinical trial experience

1998-2000 Phase 3 Study: SR-57746 in Amyotrophic Lateral Sclerosis
EudraCT No. 2005-002570-30, Investigator

2008-09 Phase 3 Study: ACR-16 in Huntington Disease,
EudraCT No. 2009-0112334-99, Investigator

2007-2014 Observational study REGISTRY (EHDN), Investigator

2010 Observational study PREDICT, Investigator

2014-ongoing Observational study ENROLL, Investigator

2014-2016 Phase 1/2 Study: BVS857 in Patients with SBMA, Investigator

2015 Phase 3 Study: LEGATO (Laquinimod in Huntington Disease), Investigator,
EudraCT No. 2014-000418-75

2015-2017 Phase 1b Study: IONIS-HTRx in with patients with Early Manifest HD,
NCT02519036, local Co-PI (Ulm)

2019-2021 Phase 3 Study: GENERATION HD, NCT03761849 Local PI (Bonn)

2020-2023 Phase 2 Study: ROCK-ALS, NCT03792490 Local PI (Bonn)


2021-2023 Phase 3 Study: MT-1186, NCT04569084 Local PI (Bonn)

2022-2023 Phase 3 Study: COURAGE-ALS, NCT04944784 Local PI (Bonn)

2022-ongoing Phase 2 Study: DAZALS, NCT05407324 Local PI (Bonn)

2023-ongoing Phase 1 Study: QRL-201, NCT05633459 Local PI (Bonn)

2023-ongoing Phase 2 Studs: GENERATION HD2, NCT05686551 Local PI (Bonn)



PD Dr. Patrick Weydt

Bonn June 12th 2024